Frazier Financial Advisors LLC Raises Stock Holdings in Novo Nordisk A/S $NVO

Frazier Financial Advisors LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 15.7% during the 2nd quarter, Holdings Channel reports. The fund owned 2,728 shares of the company’s stock after purchasing an additional 371 shares during the period. Frazier Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $188,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of NVO. Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares during the last quarter. North Capital Inc. purchased a new stake in Novo Nordisk A/S in the first quarter worth $27,000. Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S in the first quarter worth $30,000. Disciplina Capital Management LLC increased its stake in Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 297 shares during the period. Finally, Spirit of America Management Corp NY purchased a new stake in Novo Nordisk A/S in the first quarter worth $35,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 1.0%

Shares of Novo Nordisk A/S stock opened at $57.51 on Tuesday. The firm’s 50 day moving average price is $55.61 and its 200-day moving average price is $63.03. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $120.47. The company has a market cap of $256.76 billion, a P/E ratio of 15.80, a PEG ratio of 2.58 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 22.53%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NVO. BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Weiss Ratings restated a “hold (c-)” rating on shares of Novo Nordisk A/S in a research note on Saturday, September 27th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Finally, Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.